Press / Media
BRYCE OLSON’S “SEQUENCE ME” STORY (PART 2) When Bryce Olson was diagnosed with advanced prostate cancer, he sequenced the DNA of his tumor which offered important clues to new treatment options for his disease. Bryce explains his personal mission which encourages others to get genomic sequencing—how to do it, and why cancer patients should tell […]
As an advanced cancer patient who also works for one of the most innovative tech companies on the planet, Bryce lives on the edge of a space that is equal parts exhilaration and exhaustion. The exhilaration comes from his exposure to potentially life-saving biomedical insights being discovered in the industry. The exhaustion comes from trying […]
Bryce Olson was recently featured on KATU Channel 2 News in Portland, Oregon. Watch Bryce’s story and learn how gene testing helped Bryce. “The message I just really want to deliver is: demand sequencing. Demand genomic sequencing.”
The walls of Foundation Medicine’s lounge are filled with photographs of patients who have benefited from the power of genomic profiling to alter the course of their cancer care. READ this informative article by Emmy and Peabody-Award winning journalist Pierre Valette, and learn about how Foundation Medicine is focused on bringing cutting-edge science and technology […]
The rise in precision medicine, fueled by next-generation sequencing tests and increasingly by liquid biopsy as well, has given rise to treatments targeted not to cancer types (i.e. breast, prostate, lung, etc.), but to oncogenic driver mutations. Mutations that are unique to each individual. Treating patients based on a ‘one-size fits all’ strategy doesn’t take […]
Bryce Olson orchestrated his own treatment by assembling a team of scientists, requesting to have his genome sequenced and seeking out targeted therapies. READ this informative article from Forbes contributor Zina Moukheiber who regularly covers biotech, and learn how genomic sequencing data can empower patients and help them open up new doors into clinical trials, access […]